Guillain–Barre syndrome outbreak in Peru: Association with polymorphisms in IL‐17, ICAM1, and CD1

Jaramillo‐Valverde, Luis; Levano, Kelly S.; Villanueva, Isolina; Hidalgo, Meylin; Cornejo, Marco; Mazzetti, Pilar; Cornejo‐Olivas, Mario; Sánchez, Cesar; Poterico, Julio A.; Valdivia-Silva, Julio; Guio, Heinner

doi:10.1002/mgg3.960

Cited by 4 publications

(2 citation statements)

References 33 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7][8][9] However, in certain pathogens such as Hepatitis E virus, this association has not been established globally, as it was only reported in Netherlands and Bangladesh. 104 Therefore, immunogenicity of COVID-19 in the development of GBS should consider the variations between different populations, [105][106][107][108] as epidemiologic studies involving certain populations might introduce bias in reporting results.…”

Section: Discussionmentioning

confidence: 99%

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review

Aladawi

Elfil

Abu-Esheh

et al. 2021

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

Background: In January 2020, the first case of Guillain Barre syndrome (GBS) due to COVID-19 was documented in China. GBS is known to be postinfectious following several types of infections. Although causality can only be proven through large epidemiological studies, we intended to study this association by a thorough review of the literature. Methods: We searched PubMed, EMBASE, and Google scholar and included all papers with English or Spanish full text and original data of patients with GBS and recent COVID infection. Variables of interest were demographics, diagnostic investigations, and the latency between arboviral and neurological symptoms. Further variables were pooled to identify GBS clinical and electrophysiological variants, used treatments, and outcomes. The certainty of GBS diagnosis was verified using Brighton criteria. Results: We identified a total of 109 GBS cases. Ninety-nine cases had confirmed COVID-19 infection with an average age of 56.07 years. The average latency period between the arboviral symptoms and neurologic manifestations for confirmed COVID-19 cases was 12.2 d. The predominant GBS clinical and electromyography variants were the classical sensorimotor GBS and acute demyelinating polyneuropathy respectively. Forty cases required intensive care, 33 cases required mechanical ventilation, and 6 cases were complicated by death. Conclusions: Studies on COVID-19-related GBS commonly reported sensorimotor demyelinating GBS with frequent facial palsy. The time between the onset of infectious and neurological symptoms suggests a postinfectious mechanism. Early diagnosis of GBS in COVID-19 patients is important as it might be associated with a severe disease course requiring intensive care and mechanical ventilation.

show abstract

Section: Discussionmentioning

confidence: 99%

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review

Aladawi

Elfil

Abu-Esheh

et al. 2021

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

show abstract

“…(case 9, control 11) in 2019. [ 22 ] Based on a meta-analysis by Zhang et al . in 2018,[ 23 ] there was a marginally significant association between exon 2 of CD1E gene polymorphism and GBS in Caucasian population for allelic model.…”

Section: Discussionmentioning

confidence: 99%

Tumor necrosis factor-α, CD1A and CD1E genetic polymorphisms in Guillain-Barré syndrome: A study from India

Verma

Chakraborty

Jain

et al. 2023

Ann Indian Acad Neurol

View full text Add to dashboard Cite

Background: Guillain–Barré Syndrome (GBS) is an acute acquired autoimmune inflammatory disorder of peripheral nerves and roots. The pathogenesis is essentially an aberrant post-infectious immune response in a genetically susceptible host milieu. Single nucleotide polymorphisms (SNP) in genes encoding the inflammatory mediators like TNF-α, CD1A and CD1E can influence their expression and level and the susceptibility and clinical course of disease in GBS. Objective: We tried to study the susceptibility of single nucleotide polymorphisms of TNF-α and CD1 genes in Guillain–Barré Syndrome in Indian population and determine the association in terms of genotype, allele and haplotype distribution along with individual subtype, severity and clinical outcome. Methodology: In this case-control study, we investigated the single nucleotide polymorphism pattern in the promoter region of TNF-α (-308 G/A), TNF-α (-863C/A), CD1A and CD1E genes using real-time polymerase chain reaction in 75 GBS patients and analysed in comparison with 75 age and sex-matched healthy controls. Results: The findings revealed that the allelic distribution of TNF-α (-308 G/A) *A allele was associated with GBS ( P value 0.04, Odds Ratio 2.03, 95% Confidence Interval 1.01–4.07). There was no association found with genotype, haplotype combination and other allele distribution for GBS in the study. CD1A and CD1E SNPs did not reveal any susceptibility for GBS. The subtype analysis did not reveal any statistical significance, except for CD1A *G allele with AMAN subtype ( P value 0.026). The haplotypic combinations and mutant allele of TNF-α (-308 G/A), TNF-α (-863C/A), CD1A and CD1E were significantly associated with severe GBS in the study. However, there was no association of any SNP for mortality and survival of GBS in the study. Conclusion: TNF-α (-308 G/A)*A allele might confer genetic susceptibility for GBS in Indian population. CD1 genetic polymorphism could not be considered for susceptibility to GBS. TNF-α and CD1 genetic polymorphism did not affect mortality in GBS.

show abstract

Tumor necrosis factor alpha -863C/A polymorphism and Guillain-Barré Syndrome

Joob

Wiwanitkit

2020

Journal of Neuroimmunology

View full text Add to dashboard Cite

Guillain–Barre syndrome outbreak in Peru: Association with polymorphisms in IL‐17, ICAM1, and CD1

Cited by 4 publications

References 33 publications

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review

Tumor necrosis factor-α, CD1A and CD1E genetic polymorphisms in Guillain-Barré syndrome: A study from India

Tumor necrosis factor alpha -863C/A polymorphism and Guillain-Barré Syndrome

Contact Info

Product

Resources

About